Drug Trial Radar · NCT07599176
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 8, 2026
Primary completion
Jun 30, 2032
Study completion Jun 30, 2035
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.
Conditions
- Sickle Cell Disease
- Beta-thalassemia
Interventions
Total Body IrradiationRadiation
Total Body Irradiation 400 cGy
AlemtuzumabDrug
1 mg/kg
AbataceptDrug
10 mg/kg x 6
Research blood drawOther
About 5 tablespoons of blood will be collected from donors for research purposes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Donor myeloid chimerismTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.